<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00394992</url>
  </required_header>
  <id_info>
    <org_study_id>HEPATICA</org_study_id>
    <nct_id>NCT00394992</nct_id>
  </id_info>
  <brief_title>Adjuvant Xeloda Plus Eloxatin +/- Avastin After Radical Resection of Liver Metastasis of Colorectal Cancer</brief_title>
  <official_title>Randomized Phase III Study Post Radical Resection of Liver Metastasis of Colorectal Cancer: Bevacizumab in Combination With XELOX as Adjuvant Chemotherapy vs XELOX Alone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dutch Colorectal Cancer Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Dutch Colorectal Cancer Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of this study is to investigate whether the addition of the new anti-cancer&#xD;
      drug bevacizumab (Avastin) to the combination of the chemotherapeutic agents capecitabine&#xD;
      (Xeloda) and oxaliplatin (Eloxatin) reduces (slows down) the recurrence of metastatic disease&#xD;
      after a radical resection of liver metastases in patients with colorectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary therapy of colorectal cancer is surgical resection, but more than half of all&#xD;
      colorectal cancer patients eventually die of metastatic disease. Although the introduction of&#xD;
      new anticancer agents with efficacy in metastatic colorectal cancer, e.g.: oxaliplatin and&#xD;
      irinotecan, and the targeted agents cetuximab and bevacizumab has changed therapeutic&#xD;
      nihilism, chemotherapy alone has failed to cure these patients.&#xD;
&#xD;
      It is estimated that 15-20 % of colorectal cancer patients present with synchronous liver&#xD;
      metastases and approximately 50% of the patients with colorectal tumors will develop liver&#xD;
      metastases at some point during the course of their disease. In almost one third of the&#xD;
      cases, the liver was shown at autopsy to be the only site of cancer spread. This is in&#xD;
      accordance with the 20% - 45 % five-year survival obtained with surgical resection of hepatic&#xD;
      metastases.&#xD;
&#xD;
      Previous studies have not shown a clear benefit of adjuvant chemotherapy after metastasectomy&#xD;
      of liver metastases. However, most of these studies have been performed with 5-fluorouracil&#xD;
      with or without other older cytostatic drugs. Since new effective agents have been developed&#xD;
      (e.g.: capecitabine, oxaliplatin and bevacizumab), adjuvant combination treatment with these&#xD;
      agents might be more effective. These drugs have proven activity as first line palliative&#xD;
      treatment of recurrent metastases. This raises the question if this new effective treatment&#xD;
      is of value as an adjuvant treatment after metastasectomy.&#xD;
&#xD;
      As mentioned before, a two-arm EORTC study: neoadjuvant and adjuvant FOLFOX vs no&#xD;
      chemotherapy in resectable liver metastases of colorectal cancer is almost completed&#xD;
      (Nordlinger et al). It is expected that this study will show a 10% 3 year DFS benefit in&#xD;
      favour of th treatment arm. Definitive data of this trial will be released at the end of&#xD;
      2006, and will most probably lead to adjuvant treatment post metastasectomy as a standard of&#xD;
      care. In the HEPATCIA trial we anticipate on this by using adjuvant XELOX as the control arm.&#xD;
&#xD;
      As mentioned earlier, the 3-year disease free survival in patients post metastasectomy of&#xD;
      liver metastases is approximately 25%. There is no data available on the effectivity of the&#xD;
      XELOX regimen as adjuvant treatment after metastasectomy of colorectal cancer metastases. The&#xD;
      EORTC study was designed to demonstrate a 10% improvement in 3y DFS. Assuming that this study&#xD;
      is positive, 3 year DFS would be 35% in the control arm (XELOX post liver resection).&#xD;
&#xD;
      Since bevacizumab inhibits angiogenesis, which is required for growth of metastases, this&#xD;
      drug may be valuable in the adjuvant setting. Several studies investigate the value of this&#xD;
      drug in combination with fluoropyrimidines as an adjuvant regimen after resection of primary&#xD;
      colorectal cancers. However, at this moment there is no mature data available of these&#xD;
      studies. Therefore, we assume an increase in 3-year disease free survival of 10%, to 45% in&#xD;
      the XELOX and bevacizumab treatment arm.&#xD;
&#xD;
      This study will therefore evaluate patients with resectable liver metastasis without&#xD;
      extra-hepatic disease, investigating whether the capecitabine, oxaliplatin and bevacizumab&#xD;
      regimen is superior to capecitabine and oxaliplatin alone applied as adjuvant treatment, in&#xD;
      order to extent disease free and overall survival.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Data from the C08 study and Avant study&#xD;
  </why_stopped>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>3-year disease free survival, defined as the percentage of disease free patients 3 year after randomisation.</measure>
    <time_frame>study duration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival, defined as the percentage of patients alive 5 year after randomisation.</measure>
    <time_frame>study duration</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">79</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Liver Metastases</condition>
  <arm_group>
    <arm_group_label>1 oxaliplatin+capecitabine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>postoperatively oxaliplatin 130 mg/m2 i.v. day 1 plus capecitabine 1000 mg/m2 b.i.d. on day 1-14, q3w</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 oxaliplatin+capecitabine+bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>postoperatively oxaliplatin 130 mg/m2 i.v. day 1 plus bevacizumab 7.5 mg/kg on day 1 plus capecitabine 1000 mg/m2 b.i.d. on day 1-14, q3w</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin+capecitabine</intervention_name>
    <description>postoperatively oxaliplatin 130 mg/m2 i.v. day 1 plus capecitabine 1000 mg/m2 b.i.d. on day 1-14, q3w</description>
    <arm_group_label>1 oxaliplatin+capecitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin+capecitabine+bevacizumab</intervention_name>
    <description>postoperatively oxaliplatin 130 mg/m2 i.v. day 1 plus bevacizumab 7.5 mg/kg on day 1 plus capecitabine 1000 mg/m2 b.i.d. on day 1-14, q3w</description>
    <arm_group_label>2 oxaliplatin+capecitabine+bevacizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed written informed consent obtained prior to any study-specific procedures.&#xD;
&#xD;
          -  Age ≥ 18 years.&#xD;
&#xD;
          -  Liver metastases radically resected (R0 resection).&#xD;
&#xD;
          -  Study medication started ≥4 and ≤ 8 weeks post liver surgery.&#xD;
&#xD;
          -  Histologically confirmed liver metastasis of colorectal cancer after surgery.&#xD;
&#xD;
          -  ECOG performance status 0 or 1.&#xD;
&#xD;
          -  Adequate hematology: ANC ≥1.5 x 109/L, platelets ≥100 x 109/L, Hb ≥5.5 mmol/L, INR ≤&#xD;
             1.5, APTT &lt; 1.5 X UNL.&#xD;
&#xD;
          -  Adequate biochemistry: total bilirubin ≤1.5 UNL, ASAT and ALAT ≤2.5 x UNL, alkaline&#xD;
             phosphatase ≤2.5 x UNL, serum creatinine ≤1.5 UNL.&#xD;
&#xD;
          -  Urine dipstick &lt;2+ for protein.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Extrahepatic metastatic disease.&#xD;
&#xD;
          -  Prior adjuvant chemotherapy given &lt;6 months prior to detection of the liver&#xD;
             metastases.&#xD;
&#xD;
          -  Prior non colorectal malignancies.&#xD;
&#xD;
          -  Bleeding diathesis or coagulation disorders or the need for full-dose anticoagulation.&#xD;
&#xD;
          -  Major surgical procedure &lt;4 weeks prior to start of study treatment.&#xD;
&#xD;
          -  Females with a positive pregnancy test (within 14 days before treatment start) .&#xD;
&#xD;
          -  Lactating women.&#xD;
&#xD;
          -  Fertile women (&lt;2 years after last menstruation) and women of childbearing potential&#xD;
             not willing to use effective means of contraception.&#xD;
&#xD;
          -  History of psychiatric disability judged by the investigator to be clinically&#xD;
             significant, precluding informed consent or interfering with compliance for oral drug&#xD;
             intake.&#xD;
&#xD;
          -  Clinically significant (i.e. active) cardiovascular disease e.g. cerebrovascular&#xD;
             accidents (≤6 months prior to randomization), myocardial infarction (≤1 year prior to&#xD;
             randomization), uncontrolled hypertension while receiving chronic medication, unstable&#xD;
             angina, New York Heart Association (NYHA) Grade II or greater congestive heart&#xD;
             failure, or serious cardiac arrhythmia requiring medication.&#xD;
&#xD;
          -  Lack of physical integrity of the upper gastrointestinal tract, malabsorption&#xD;
             syndrome, or inability to take oral medication.&#xD;
&#xD;
          -  Known peripheral neuropathy, including oxaliplatin induced neuropathy &gt; grade Absence&#xD;
             of deep tendon reflexes as the sole neurological abnormality does not render the&#xD;
             patient ineligible.&#xD;
&#xD;
          -  Organ allografts requiring immunosuppressive therapy.&#xD;
&#xD;
          -  Serious, non-healing wound, ulcer, or bone fracture.&#xD;
&#xD;
          -  Current or recent (within 10 days prior to study treatment start) use of full-dose&#xD;
             oral or parenteral anticoagulants or thrombolytic agent for therapeutic purposes.&#xD;
&#xD;
          -  Chronic, daily treatment with high-dose asprin (&gt; 325 mg/day) or nonsteroidal&#xD;
             anti-inflammatory medications (those known to inhibit platelet function at doses used&#xD;
             to treat chronic inflammatory diseases). Patients can be rendered eligible by changing&#xD;
             the treatment to COX II inhibitors.&#xD;
&#xD;
          -  Chronic treatment with corticosteroids (dose of ≥ 10 mg/day methylprednisolone&#xD;
             equivalent excluding inhaled steroids).&#xD;
&#xD;
          -  Serious intercurrent infections (uncontrolled or requiring treatment).&#xD;
&#xD;
          -  Current or recent (within the 28 days prior to randomization) treatment with another&#xD;
             investigational drug or participation in another investigational study.&#xD;
&#xD;
          -  Patients with known allergy to Chinese hamster Ovary cell proteins or other&#xD;
             recombinant human or humanized antibodies or to any excipients of bevacizumab&#xD;
             formulation, platinum compounds or to any other component of the study drugs.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard van Hillegersberg, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitair Medisch Centrum Utrecht</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3508 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.dccg.nl</url>
    <description>Websites Dutch Colorectal Cancer Group</description>
  </link>
  <link>
    <url>http://www.umcutrecht.nl/research/</url>
    <description>University Medical Center Utrecht</description>
  </link>
  <verification_date>February 2014</verification_date>
  <study_first_submitted>November 1, 2006</study_first_submitted>
  <study_first_submitted_qc>November 1, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2006</study_first_posted>
  <last_update_submitted>February 3, 2014</last_update_submitted>
  <last_update_submitted_qc>February 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Colorectal cancer</keyword>
  <keyword>Liver metastasis</keyword>
  <keyword>Radical resection</keyword>
  <keyword>Adjuvant therapy</keyword>
  <keyword>Bevacizumab</keyword>
  <keyword>Capecitabine</keyword>
  <keyword>Oxaliplatin</keyword>
  <keyword>Hepatica</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

